Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241065 | 0.86 | NPC1 (0.36) | NPC1DGAT1MAPT | |
| SCHEMBL30442857 | 0.86 | NPC1 (0.36) | NPC1DGAT1MAPT | |
| SCHEMBL29959046 | 0.85 | NPC1 (0.37) | NPC1DGAT1MAPTHTT | |
| SCHEMBL4817809 | 0.85 | NPC1 (0.37) | NPC1DGAT1MAPTHTT | |
| SCHEMBL20839775 | 0.84 | NPC1 (0.38) | NPC1DGAT1MAPT | |
| SCHEMBL20839822 | 0.84 | NPC1 (0.35) | NPC1DGAT1MAPT | |
| SCHEMBL20443899 | 0.84 | HTT (0.34) | HTT | |
| SCHEMBL23326952 | 0.81 | NPC1 (0.38) | NPC1MAPTHTT | |
| SCHEMBL20839901 | 0.79 | NPC1 (0.32) | NPC1MAPT | |
| SCHEMBL2238224 | 0.79 | MAPT (0.35) | NPC1DGAT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3679039-B1 | TYROSINE ANALOGUES DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2021-06-16 | — | — | EP | disclosed |
| WO-2019048479-A1 | TYROSINE ANALOGUES DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-03-14 | — | — | WO | disclosed |
| US-20180215758-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215758-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, CIT | NPC1 4064/4885DGAT1 2711/4885MAPT 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.